Our team

Board of Directors

Luis Sánchez-Lafuente


Former Chief Executive Officer and co-owner of Laboratorios Gelos, SA. President of AB Biotics, SA

Miquel Àngel Bonachera

Vice Chairman

Chief executive officer and co-founder of AB Biotics, SA.
BSc/MSc in biochemistry and MBA.

Sergi Audivert

Secretary general

Chief executive officer and co-founder of AB Biotics, SA. 
BSc/MSc in food technology and MBA.

Josep Maria Echarri i Torres

CEO and co-founder of Inveready Seed Capital SCR.
President of Inveready Capital Company.
Co-founder of Oryzon Genomics, SA

Carles Domènech

Chief Executive Officer of Ability Pharmaceuticals, SL
Carles obtained a BSs/MSc degree in biology (first class honors) from the Autonomous University of Barcelona and also a PhD degree in cellular biology from the same University, working at the Council of Science Research (CSIC). He has additional business training at ESADE business school and other business programs.

After his career in CSIC in Barcelona (1985-89) and at Memorial Sloan-Kettering Cancer Center in New York (1990-1992), he held senior positions at  Almirall, SA (1992-2003) as Manager and Head of Business Development and Licensing and Lacer, SA (2005-2007) as Director, Business Development and Licensing.

Carles has also 4 years experience in biotech venture capital and business angels associations and has also been collaborating with government innovation agencies. Between 2004 and 2005 he was Director, Biotech Investments at the seed venture capital firm Barcelona Emprèn, SCRSA. During 2008-2009 he collaborated with agencies of the Government of Catalonia as Director, Technology Transfer and Valorization and as Managing Director, Investment and Enterprise Growth. He had under his responsibility the seed venture capital company Invertec, SA and the entrepreneurship finance programs Genesis Capital and Concept Capital. Since July 2009 he also advises Keiretsu Forum Barcelona in biotech investments.

In 2009 Carles cofounded Ability Pharmaceuticals, SL to become its Chief Executive Officer in September 2009

Roger Piqué

Managing director and co-founder of Inveready Seed Capital SCR.

José Manuel Valadés

Lawyer, partner and founder of the law firm Alliant Abogados




AbilityPharma rises € 3.5 million in a financing round to complete the current oncologic phase 2 clinical trial and license ABTL0812 to an international pharmaceutical company + info


Ability Pharmaceuticals Announces the Presentation of the First Results of ABTL0812 as First Line in Patients with Endometrial or Lung Cancer at 2019 ASCO Annual Meeting + info


Ability Pharmaceuticals Announces the Approval in China of a Clinical Study in Pancreatic Cancer with ABTL0812 + info


Ability Pharmaceuticals is attending the BIOMED EVENT® by INVEST SECURITIES and the Cholangiocarcinoma Foundation Annual Conference + info


AbilityPharma ha superado el millón de euros en la ronda de crowdfunding que abrió el pasado mes de septiembre + info


Ability Pharmaceuticals Announces FDA-Orphan Drug Designation for ABTL0812 in Biliary Tract Cancer + info


Ability Pharmaceuticals anuncia la inclusión del primer paciente en el estudio clínico de la fase 2 de ABTL0812 en Francia + info


At AbilityPharma we are very pleased to announce the start of a crowdfunding campaign through de Capital Cell + info


AbilityPharma Announces FDA Approval of Phase 1/2 Trial of ABTL0812 for Patients with Advanced Metastatic Pancreatic Cancer + info
© 2012 Ability Pharma / All Rights Reserved / Legal Notice / Privacy Police